High-throughput drug screening identifies hdac inhibitors as candidate therapeutics for myc-driven medulloblastoma.

Journal Article

Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MBs with high levels of the MYC oncogene have a particularly poor prognosis, and would benefit from novel therapies.

Full Text

Duke Authors

Cited Authors

  • Wechsler-Reya, RJ; Pei, Y; Liu, KW; Wang, J; Esparza, LA; Maier, DL; Li, XN; Cho, YJ

Published Date

  • July 2014

Published In

Volume / Issue

  • 16 Suppl 3 /

Start / End Page

  • iii29 -

PubMed ID

  • 25165271

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nou208.22

Language

  • eng

Conference Location

  • England